

## AMOREPACIFIC <br> GROUP

## AMOREPACIFIC GROUP 102017 Earnings Release

1 102017 Earnings Summary
2 Earnings by Subsidiary
3 Financial Summary

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.
AMOREPACIFIC Group has adopted the K-IFRS since 2011.

IR ${ }_{2001}^{\text {! }} 102017$ Earnings Summary

Sales up 5.5\% to 1,855.4 billion, OP down 9.7\% to 378.5 billion

Sales \& OP by Division
KRW bn

|  | 201610 | 201710 | YoY(\%) |
| :---: | :---: | :---: | :---: |
| Sales | 1,759.3 | 1,855.4 | 5.5 |
| Beauty Subsidiaries 1) | 1,807.7 | 1,914.6 | 5.9 |
| Non-Beauty Subsidiaries 2) | 47.7 | 44.5 | -6.6 |
| Others 3) | -96.0 | -103.8 |  |
|  | 201610 | 201710 | YoY(\%) |
| Operating Profit (OPM) | 419.1 (23.8\%) | 378.5 (20.4\%) | -9.7 |
| Beauty Subsidiaries (OPM) | 408.3 (22.6\%) | 380.9 (19.9\%) | -6.7 |
| Non-Beauty Subsidiaries (OPM) | 5.8 (12.2\%) | -3.2 (-7.1\%) | Turned to Red |
| Others | 5.0 | 0.8 |  |
| Net profit (Margin) | 325.3 (18.5\%) | 266.2 (14.3\%) | -18.2 |

IR ${ }_{200}^{10} \mid$ Earnings by Subsidiary(1/3)

Beauty subsidiaries


Non-Beauty subsidiaries
Sales


## AMOREPACIFC Sales +6\%, OP - $6 \%$

## Domestic

- (Luxury) Increased sales of skin care and inner beauty category, expanded customer communication by strengthening digital competiveness, expanded opportunities for brand experience through diverse offline marketing activities, slowdown in revenue growth for travel retail due to decrease in inflow of foreign tourists
- (Premium) Revenue growth from strong sales of make-up products, strengthened channel competiveness through innovative spaces to experience brands and sales competency


## Mass \& OSulloc

- (Mass) Revenue growth due to steady sales from hair and body care categories
- (OSulloc) Online/Offline channel restructuring for quality growth


## Overseas

- Asia region sustained sales growth and expanded new stores mainly for the 5 major global champion brands
- North America business increased investment and restructured business portfolio
- Europe business terminated license with Lolita Lempicka brand, increased investment in Annick Goutal brand


## Innisfree Sales +6\%, OP -11\%

- Revenue increased through launch of new Jeju-origin products('Bija Cica Balm,' 'Jeju Lava Seawater Ampoule’) and steady sales of key products ('The Green Tea Seed Serum,' ‘Jeju Orchid Enriched Cream,' 'My Cushion’). However, sales slowdown in travel retail channel due to decrease in inflow of foreign tourists
- Innisfree increased investment to heighten on/off customer experience by expanding green lounge (powder room to experience products), strengthening online exclusive products and etc.


## Etude Sales 0\%, OP-29\%

- Enhanced brand appeal through new product launches ('Fix \& Fix Primer,' 2017 S/S make-up collection 'Wonderfun Park Collection, ' 'Dear My Glass Tinting Lips Talks' and etc.) and increased marketing investment
- Sales slowdown in travel retail channel due to decrease in inflow of foreign tourists

|  | AMOREPACIFIC _ Consolidated |  |  |
| :---: | :---: | :---: | :---: |
|  | 201610 | 201710 | YoY |
| Sales | 1,485.1 | 1,569.0 | 6\% |
| GP | 1,136.5 | 1,183.0 | 4\% |
| SG\&A expenses | 798.7 | 866.2 | 8\% |
| OP | 337.8 | 316.8 | -6\% |
|  |  | Innisfree |  |
| Sales | 186.6 | 198.4 | 6\% |
| GP | 136.5 | 142.4 | 4\% |
| SG\&A expenses | 84.6 | 96.1 | 14\% |
| OP | 51.9 | 46.3 | -11\% |
|  |  | Etude |  |
| Sales | 81.4 | 81.3 | 0\% |
| GP | 48.0 | 49.3 | 3\% |
| SG\&A expenses | 35.7 | 40.5 | 13\% |
| OP | 12.3 | 8.8 | -29\% |

## IR ${ }^{10}$ <br> 10 2017 <br> Earnings by Subsidiary(3/3)

## Espoir Sales $+47 \%$, Turned to Black

- Turned to black and achieved robust revenue growth through solid sales from travel retail and online channel
- Strengthened its competiveness as a professional make-up brand through new product launches ('Pro Atelier Collection,' 'Coralude Collection') which highlights differentiated make-up looks


## Aestura Sales +14\%, OP +140\%

- Increase in revenue growth through stronger sales of inner beauty products and medical beauty brand (Meditoxin, Atobarrier)
- Improved profitability through efficient cost management


## Amos Professional Sales $+18 \%$, OP $+23 \%$

- Increase in revenue and profit through stronger sales of representative products ('Colorgenic True Sync S,' 'Feel the Green Tea,’ 'Curling Essence’ and etc.) and robust growth from travel retail channel
- Strengthened brand awareness through diverse marketing activities ('Salon Inspiration seminar,' 'Got Night' campaign)

|  | Espoir |  |  |
| :---: | :---: | :---: | :---: |
|  | 201610 | 201710 | YoY |
| Sales | 8.5 | 12.5 | 47\% |
| GP | 6.9 | 10.3 | 48\% |
| SG\&A expenses | 7.1 | 9.8 | 37\% |
| OP | -0.2 | 0.5 | Turned to Black |
|  | Aestura (Pacific Pharma.) |  |  |
| Sales | 24.3 | 27.7 | 14\% |
| GP | 5.9 | 6.2 | 6\% |
| SG\&A expenses | 5.4 | 5.0 | -6\% |
| OP | 0.5 | 1.2 | 140\% |
|  | Amos Professional |  |  |
| Sales | 21.8 | 25.7 | 18\% |
| GP | 12.8 | 16.0 | 25\% |
| SG\&A expenses | 6.9 | 8.8 | 27\% |
| OP | 5.9 | 7.3 | 23\% |

$\mathbf{I R}_{200 \mid}^{100}$ | Financial Summary

Income Statement

| Sales | 201610 |  | 201710 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | $1,759.3$ | $100.0 \%$ | $1,855.4$ | $100.0 \%$ |
| SG\&A expenses | 932.2 | $53.0 \%$ | $1,029.9$ | $55.5 \%$ |
| Operating Profit | 419.1 | $23.8 \%$ | 378.5 | $20.4 \%$ |
| Non-operating <br> Profit/Expenses | 8.2 |  | $1,408.4$ | $75.9 \%$ |
| Profit before tax | 427.3 | $24.3 \%$ | 353.6 | $19.1 \%$ |
| Consolidated net <br> income | 325.3 | $18.5 \%$ | 266.2 | $14.3 \%$ |

Statements of Financial Position

|  | 2016.12 | 2017.03 |
| :---: | :---: | :---: |
| Assets | 7,088.4 | 7,404.0 |
| Current assets | 2,942.6 | 3,238.9 |
| Non-current assets | 4,145.8 | 4,165.0 |
| Liabilities | 1,521.5 | 1,715.9 |
| Current liabilities | 1,321.1 | 1,503.9 |
| Non-current liabilities | 200.4 | 212.0 |
| Shareholder's Equity | 5,566.9 | 5,688.1 |
| Capital stock | 44.5 | 44.5 |
| Additional paid-in capital | 673.0 | 673.0 |
| Capital surplus | 22.6 | 22.6 |
| Other components of equity | -146.0 | -146.0 |
| Accumulated other comprehensive income | -11.9 | -19.3 |
| Retained earnings | 2,251.0 | 2,317.8 |
| Non-controlling interest | 2,733.6 | 2,795.5 |

